



Performance

2022 was a year in which we set all-time highs in several financial categories—including Revenue and Adjusted Diluted EPS.

Learn more about our performance on our [Investor site](#).

Financial Performance

Three-year summary for the years ended December 31

Millions, Except Per Share Data				% Change	
	2022	2021	2020	22/21	21/20
Revenues	\$ 100,330	\$ 81,288	\$ 41,651	23	95
Reported net income ^(a)	\$ 31,372	\$ 21,979	\$ 9,159	43	*
Reported diluted EPS ^(a)	\$ 5.47	\$ 3.85	\$ 1.63	42	*
Adjusted income ^(b)	\$ 37,717	\$ 23,196	\$ 12,601	63	84
Adjusted diluted EPS ^(b)	\$ 6.58	\$ 4.06	\$ 2.24	62	82
Net cash provided by operating activities	\$ 29,267	\$ 32,580	\$ 14,403	(10)	*
Cash dividends paid	\$ 8,983	\$ 8,729	\$ 8,440	3	3

* Indicates calculation not meaningful.

^(a) Reported net income is defined as *Net income attributable to Pfizer Inc. common shareholders* in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.


^(b) Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP *Net income attributable to Pfizer Inc. common shareholders* and reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. The Adjusted income and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the *Non-GAAP Financial Measure: Adjusted Income* section of [Management's Discussion and Analysis of Financial Condition and Results of Operations](#) in Pfizer's 2022 Annual Report on Form 10-K for an explanation of how management uses these non-GAAP measures, reconciliations to the most directly comparable U.S. GAAP measures and additional information.

Detailed information on our financial and operational performance can be found in our 2022 Annual Report on Form 10-K.

Top 10 Medicines and Vaccines

Take a look at our breakdown of the top medicines and vaccines by revenue from 2022.

- **\$37,806 million**
 (38% of total revenue)
COMIRNATY⁰¹
- **\$18,933 million**
 (19% of total revenue)
PAXLOVID[®] (nirmatrelvir tablets and ritonavir tablets)
- **\$6,480 million**
 (6% of total revenue)
ELIQUIS[®] (apixaban)²
- **\$6,337 million**
 (6% of total revenue)
PREVNAR[®] Family³
- **\$5,120 million**
 (5% of total revenue)
IBRANCE[®] (palbociclib)
- **\$2,447 million**
 (2% of total revenue)
VYNDAQEL[®] Family⁴
- **\$1,796 million**
 (2% of total revenue)
XELJANZ[®] (tofacitinib)
- **\$1,198 million**
 (1% of total revenue)
XTANDI[®] (enzalutamide)⁵
- **\$1,003 million**
 (1% of total revenue)
ENBREL[®] (etanercept)
- **\$1,003 million**
 (1% of total revenue)
INLYTA[®] (axitinib)



[View the interactive graph on the Annual Review site.](#)

¹ COMIRNATY refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), the COMIRNATY Original/Omicron BA.1 Vaccine, and COMIRNATY Original/Omicron BA.4/BA.5 Vaccine. COMIRNATY includes direct sales and alliance revenues related to sales of the above-mentioned vaccines.

² ELIQUIS includes alliance revenues and direct sales.

³ PREVNAR Family includes revenues from PREVNAR 13/PREVENAR 13 (pediatric and adult) and PREVNAR 20/APEXXNAR (adult).

⁴ VYNDAQEL Family includes global revenues from VYNDAQEL, as well as revenues for VYNDAMAX in the U.S. and VYNNAC in Japan.

⁵ XTANDI represents alliance revenues.